57 / 69
57
response to nilotinib in Philadelphia chromosome-positive
chronic myeloid leukemia. Hematologica 2010;95:582-8.
22.
Haus O, Noworolska A, Laskowski M, Kuliszkiewicz-
Janus M, Kozlowska J, Harlozinska-Szmyrka A, et al.
Prognostic Significance of Secondary Cytogenetic Changes
and Nonspecific Cross-reacting Antigen (NCA) in Patients
with Ph-Positive Chronic Myeloid Leukemia. Exp Mol
Pathol 1990;52:235-42.
23.
Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS,
et al. Additional chromosome abnormalities in chronic
myeloid leukemia. Kaohsiung J Med Sci 2011;27:49-54.
24.
Vranová V, Katina S, Kirschnerová G, Mistrík M, Lakota J,
Horáková J, et al. A significance of additional
chromosomal aberrations and other variables on post
transplantation outcome of patients with CML. Neoplasma
2005;52:381-7.
25.
Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein
B, Haferlach C, et al. Impact of additional cytogenetic
aberrations at diagnosis on prognosis of CML: long-term
observation of 1151 patients from the randomized CML
Study IV. Blood 2011;118:6760-8.
26.
Ahmed R, Naqi N, Hussain I, Khattak BK, Nadeem M,
Iqbal J. Presentating phases of chronic myeloid leukaemia.
J Coll Physicians Surg Pak 2009;19:469-72.
27.
Cortes J, Kantarjian H. Advanced-phase chronic myeloid
leukemia. Semin Hematol 2003;40:79-86.
28.
Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G,
Ferrajoli A, et al. Staging of chronic myeloid leukemia in
the imatinib era: an evaluation of the World Health
Organization proposal. Cancer 2006;106:1306-15.
29.
Cortes J. Natural history and staging of chronic
myelogenous leukemia. Hematol Oncol Clin North
Am 2004;18:569-84.